-
immature dendritic cell
Immature DC (imDC´s) are transfected with different constructs encoding for the oncogene Her-2/neu and as control PSA. The technology of Amaxa biosystems or an adeno virus Her-2 full length construct are used.
-
dendritic cell
These cells were stained by Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling, from Sigma) in order to analyse their uptake of dead cells.
-
dendritic cell
Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial.
-
dendritic cell
We also show that DCs derived from ashen mice, which are defective for the small GTPase Rab27a, fail to cross present antigens efficiently, due to increased phagosome acidification and antigen degradation. This defect in Rab27a-deficient DCs results from the impaired recruitment to phagosomes of the NOX2 membrane components. Therefore phagosomal alkalinization by NOX2 is controlled by Rab27a, and is required for efficient cross presentation in DCs.
-
dendritic cell
RCC product that was tested in an RCC phase 2 trial. The product does indeed lead to restoration of both IL-2 and IFN responses and leads to a gradual decline of the immune effector T cells in the peripheral circulation (i.e., weaker signal after the fifth dose). Using the PME-CD40L DC product we have observed tumor regressions in a number of patients in the current study. At present, 6 of 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier).
-
myeloid dendritic cell
We found that BM-myeloid and splenic CD8alpha+ DC produced at least fivefold less IL-12p70 than plasmacytoid pDC responding to both CpG and the TLR-7 ligand R848.
-
myeloid dendritic cell
We found that CD8alpha- DC produced undetectable levels of IL-12p70 upon stimulation with CpG.
-
dendritic cell
We have stimulated human Monocyte derived Dendritic Cells (hMoDC) with yeast, spheroplasts, pseudohyphae, spores, purified RNA and not purified RNA, LPS.
-
dendritic cell
These DC were used in an experiment for identification of antigens recognised by T cells from melanoma patients responding to immunotherapy.
-
dendritic cell
A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. We have identified 2794 proteins in DCs by liquid chromatography tandem mass spectrometry. Prior to MS analysis, DC were lysed and divided into a soluble fraction containing cytosolic proteins and into an insoluble fraction enriched for membrane containing proteins. Hi
...
-
dendritic cell
These DC pulsed with MAGE-A3, gp100, NA17 and tyrosinase were used for vaccination of melanoma patients.
-
dendritic cell
The cDNA’s encoding these early expressed HIV antigens have been human codon optimized and modified with lysosomal targeting sequences.
-
dendritic cell
These dendritic cells were generated with GM-CSF and IL-4. They were used in a clinical trial in melanoma patients who were randomized to receive immunizations either with these G4 DC or with I3 DC (DC generated with interferon-beta and interleukin-3).
-
dendritic cell
These dendritic cells were generated with interferon-beta and interleukin-3. They were used in a clinical trial in melanoma patients who were randomized to receive immunizations either with these I3 DC or with G4 DC (DC generated with GM-CSF and IL-4).
-
dendritic cell
These autologous DC were used in a phase IB/II study of immunotherapy. Patients were randomized to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4).
-
dendritic cell
We have studied the immuno-physiology of rat and mouse intestinal dendritic cells. We have used a known adjuvant, E. coli heat-labile toxin (Etx) and a potential adjuvant R-848, a small TLR7/8 ligand.
-
dendritic cell
We wanted to assess whether functional activation of human monocyte-derived DCs can be achieved by electroporation of an activation signal in the form of double-stranded (ds) RNA and whether simultaneous electroporation of the dsRNA with tumor antigen encoding mRNA can lead to the induction of a cytotoxic T-lymphocyte (CTL) response.
-
dendritic cell
We have analyzed the uptake, conservation and cross-presentation of the model antigen OVA after Fc receptor-mediated uptake by DC. We found that MHC class I presentation is relatively short-lived in contrast to MHC class II. However, CD8 cross-priming capacity of OVA-loaded DC was functionally retained for many days, while peptide-pulsed DC had lost their priming capacity after 24 hours.
-
dendritic cell
We have analyzed the uptake, conservation and cross-presentation of the model antigen OVA after Fc receptor-mediated uptake by DC. We found that MHC class I presentation is relatively short-lived in contrast to MHC class II. However, CD8 cross-priming capacity of OVA-loaded DC was functionally retained for many days, while peptide-pulsed DC had lost their priming capacity after 24 hours.
-
dendritic cell
We have demonstrated that the NADPH oxidase NOX2 is recruited to DC early phagosomes mediating a sustained production of low levels of reactive oxygen species and causing a maintained alkalynization of the phagosomal lumen. DCs lacking NOX2 show increased antigen degradation due to an enhanced phagosome acidification. As a result, the efficiency of in vitro and in vivo antigen cross presentation is significantly reduced in NOX2-deficient DCs.